{"nctId":"NCT00363415","briefTitle":"Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer","startDateStruct":{"date":"2006-08"},"conditions":["Small Cell Lung Cancer"],"count":908,"armGroups":[{"label":"A","type":"EXPERIMENTAL","interventionNames":["Drug: pemetrexed","Drug: carboplatin"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: etoposide","Drug: carboplatin"]}],"interventions":[{"name":"pemetrexed","otherNames":["LY231514","Alimta"]},{"name":"etoposide","otherNames":[]},{"name":"carboplatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of extensive stage small cell lung cancer (SCLC)\n* Capable of self-care but may be unable to carry out any work activities.\n* No prior anticancer therapy for SCLC\n\nExclusion Criteria:\n\n* have previously participated in a study involving pemetrexed\n* have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Subgroups)","description":"The effects of individual baseline factors (sex, race, Eastern Cooperative Oncology Group (ECOG) performance, region, lactate dehydrogenase (LDH), age, number of metastatic sites, and history of brain metastases) on overall survival are reported. For two subgroups - LDH\\<=upper limit of normal and brain metastases=yes, the upper limits of the 95% confidence interval were not calculable for the etoposide+carboplatin group - instead the number of participants in these two subgroups are presented as a post-hoc outcome measure.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"11.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"8.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"11.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"9.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"11.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival","description":"The period from study entry until disease progression, death or date of last contact.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Each Cycle in Functional Assessment of Cancer Therapy - Lung (FACT-L)","description":"FACT-L measures following domains of health-related quality of life (HR-QL): physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns of lung cancer. Total scores range from 0 to 136, with higher scores representing better HR-QL. A clinically meaningful change is considered to be 5 points.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.42","spread":"15.40"},{"groupId":"OG001","value":"87.79","spread":"16.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"12.48"},{"groupId":"OG001","value":"1.55","spread":"11.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"13.72"},{"groupId":"OG001","value":"1.73","spread":"12.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"14.61"},{"groupId":"OG001","value":"1.70","spread":"13.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"15.28"},{"groupId":"OG001","value":"1.69","spread":"13.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"16.34"},{"groupId":"OG001","value":"1.94","spread":"14.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"17.56"},{"groupId":"OG001","value":"3.73","spread":"14.97"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Subgroups: LDH<=Upper Limit of Normal and History of Brain Metastases=Yes)","description":"The effects of individual baseline factors (lactate dehydrogenase (LDH) and history of brain metastases) on overall survival are reported. The Upper Limits of the 95% Confidence Intervals were not calculable for these factors in the Etoposide+Carboplatin group. The number of participants in these subgroup are instead presented as a Post-Hoc Outcome Measure.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[]},{"type":"POST_HOC","title":"Number of Participants in Subgroups: LDH<=Upper Limit of Normal and History of Brain Metastases=Yes","description":"Number of participants with Low Density Lipoprotein \\<=upper limit of normal and the number of participants with a history of brain metastases. This post-hoc outcome replaces the one for Overall Survival (Subgroups: LDH\\<=Upper Limit of Normal and History of Brain Metastases=Yes).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"169","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":150},"commonTop":["Cough","Dyspnoea","Hypertension","Fatigue","Neutropenia"]}}}